Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 8/2016

01-08-2016 | Review

Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers

Authors: Kwaku Appiah-Kubi, Ying Wang, Hai Qian, Min Wu, Xiaoyuan Yao, Yan Wu, Yongchang Chen

Published in: Tumor Biology | Issue 8/2016

Login to get access

Abstract

Progress in cancer biology has led to an increasing discovery of oncogenic alterations of the platelet-derived growth factor receptors (PDGFRs) in cancers. In addition, their overexpression in numerous cancers invariably makes PDGFRs and platelet-derived growth factors (PDGFs) prognostic and treatment markers in some cancers. The oncologic alterations of the PDGFR/PDGF system affect the extracellular, transmembrane and tyrosine kinase domains as well as the juxtamembrane segment of the receptor. The receptor is also involved in fusions with intracellular proteins and receptor tyrosine kinase. These discoveries undoubtedly make the system an attractive oncologic therapeutic target. This review covers elementary biology of PDGFR/PDGF system and its role as a prognostic and treatment marker in cancers. In addition, the multifarious therapeutic targets of PDGFR/PDGF system are discussed. Great potential exists in the role of PDGFR/PDGF system as a prognostic and treatment marker and for further exploration of its multifarious therapeutic targets in safe and efficacious management of cancer treatments.
Literature
1.
Cao Y. Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis. Trends Mol Med. 2013;19(8):460–73.PubMedCrossRef
2.
3.
Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology. 2008;47 suppl 5:v2–4.PubMedCrossRef
4.
Miyata T, Toho T, Nonoguchi N, Furuse M, Kuwabara H, Yoritsune E, et al. The roles of platelet-derived growth factors and their receptors in brain radiation necrosis. Radiat Oncol. 2014;9:51.PubMedPubMedCentralCrossRef
5.
Kumabe T, Sohma Y, Kayama T, Yoshimoto T, Yamamoto T. Overexpression and amplification of alpha-PDGF receptor gene lacking exons coding for a portion of the extracellular region in a malignant glioma. Tohoku J Exp Med. 1992;168(2):265–9.PubMedCrossRef
6.
Clarke I, Dirks P. A human brain tumor-derived PDGFR-α deletion mutant is transforming. Oncogene. 2003;22(5):722–33.PubMedCrossRef
7.
Cheung YH, Gayden T, Campeau PM, LeDuc CA, Russo D, Nguyen V-H, et al. A recurrent PDGFRB mutation causes familial infantile myofibromatosis. Am J Hum Genet. 2013;92(6):996–1000.PubMedPubMedCentralCrossRef
8.
Gilbertson RJ, Langdon JA, Hollander A, Hernan R, Hogg TL, Gajjar A, et al. Mutational analysis of PDGFR–RAS/MAPK pathway activation in childhood medulloblastoma. Eur J Cancer. 2006;42(5):646–9.PubMedCrossRef
9.
Toffalini F, Demoulin J-B. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood. 2010;116(14):2429–37.PubMedCrossRef
10.
Reilly JT. Receptor tyrosine kinases in normal and malignant haematopoiesis. Blood Rev. 2003;17(4):241–8.PubMedCrossRef
11.
Tarn C, Godwin AK. The molecular pathogenesis of gastrointestinal stromal tumors. Clin Colorectal Cancer. 2006;6:S7–17.PubMedCrossRef
12.
Demoulin J-B, Essaghir A. PDGF receptor signaling networks in normal and cancer cells. Cytokine Growth Factor Rev. 2014.
13.
Ozawa T, Brennan CW, Wang L, Squatrito M, Sasayama T, Nakada M, et al. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev. 2010;24(19):2205–18.PubMedPubMedCentralCrossRef
14.
Cimpean AM, Ceauşu R, Encică S, Gaje PN, Ribatti D, Raica M. Platelet-derived growth factor and platelet‐derived growth factor receptor‐α expression in the normal human thymus and thymoma. Int J Exp Pathol. 2011;92(5):340–4.PubMedPubMedCentralCrossRef
15.
Matei D, Kelich S, Cao L, Menning N, Emerson RE, Rao J, et al. PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biol Ther. 2007;6(12):1951–9.PubMedCrossRef
16.
Kubo T, Piperdi S, Rosenblum J, Antonescu CR, Chen W, Kim HS, et al. Platelet‐derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer. 2008;112(10):2119–29.PubMedCrossRef
17.
Chu JS, Ge FJ, Zhang B, Wang Y, Silvestris N, Liu LJ, et al. Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res. 2013;32(1):1–8. doi:10.​1186/​1756-9966-32-16.CrossRef
18.
Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest. 2006;116(6):1561.PubMedPubMedCentralCrossRef
19.
Gomez-Casal R, Bhattacharya C, Ganesh N, Bailey L, Basse P, Gibson M, et al. Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. Mol Cancer. 2013;12(1):94.PubMedPubMedCentralCrossRef
20.
Carnero A, Moneo Ocaña V. PDGFR-α as response marker for PM00104 treatment. 2009.
21.
Kurokawa Y, Matsuura N, Kawabata R, Nishikawa K, Ebisui C, Yokoyama Y, et al. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer. Ann Surg Oncol. 2014;21(4):584–90.CrossRef
22.
Cerchia L, Condorelli G, De Franciscis V. Neutralizing RNA aptamers against PDGFbeta and uses thereof in the therapy and diagnosis of hyperproliferative diseases. Google Patents; 2013.
23.
Gérard C, Debruyne C. Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer. Mol Oncol. 2009;3(5):409–24.PubMedCrossRef
24.
25.
Pietras K, Rubin K, Sjöblom T, Buchdunger E, Sjöquist M, Heldin C-H, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002;62(19):5476–84.PubMed
26.
Lu C, Shahzad MM, Moreno-Smith M, Lin Y, Jennings NB, Allen JK, et al. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther. 2010;9(3):176–82.PubMedPubMedCentralCrossRef
27.
Roy K, Kanwar R, Kanwar J. Targeted inhibition of tumour vascularisation using anti-PDGF/VEGF aptamers. Austin J Nanomed Nanotechnol. 2014;2(5):7.
28.
Rosenzweig SA. Acquired resistance to drugs targeting receptor tyrosine kinases. Biochem Pharmacol. 2012;83(8):1041–8.PubMedCrossRef
29.
Liu J, Liao S, Huang Y, Samuel R, Shi T, Naxerova K, et al. PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2011;17(11):3638–48. doi:10.​1158/​1078-0432.​CCR-10-2456.CrossRef
30.
Wang B, Rosano JM, Cheheltani RE, Achary MP, Kiani MF. Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer. Expert Opin Drug Deliv. 2010;7(10):1159–73.PubMedCrossRef
31.
Rajkumar VS, Boxer G, Robson M, Muddle J, Papastavrou Y, Pedley RB. A comparative study of PDGFR inhibition with imatinib on radiolabeled antibody targeting and clearance in two pathologically distinct models of colon adenocarcinoma. Tumor Biol. 2012;33(6):2019–29.CrossRef
32.
Chen P-H, Chen X, He X. Platelet-derived growth factors and their receptors: structural and functional perspectives. Biochim Biophys Acta (BBA)-Proteins Proteomics. 2013;1834(10):2176–86.CrossRef
33.
Omura T, Heldin C-H, Östman A. Immunoglobulin-like domain 4-mediated receptor-receptor interactions contribute to platelet-derived growth factor-induced receptor dimerization. J Biol Chem. 1997;272(19):12676–82.PubMedCrossRef
34.
Heldin C-H, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79(4):1283–316.PubMed
35.
Gueller S, Hehn S, Nowak V, Gery S, Serve H, Brandts CH, et al. Adaptor protein Lnk binds to PDGF receptor and inhibits PDGF-dependent signaling. Exp Hematol. 2011;39(5):591–600.PubMedCrossRef
36.
Jiang L, Chen Y, Sang J, Li Y, Lan T, Wang Y, et al. Type II cGMP-dependent protein kinase inhibits activation of key members of the RTK family in gastric cancer cells. Biomed Rep. 2013;1(3):399–404.PubMedPubMedCentral
37.
Schmidt Y, Simunovic F, Strassburg S, Pfeifer D, Stark GB, Finkenzeller G. miR-126 regulates platelet-derived growth factor receptor-α expression and migration of primary human osteoblasts. Biol Chem. 2015;396(1):61–70.PubMedCrossRef
38.
Boström H, Gritli-Linde A, Betsholtz C. PDGF-a/PDGF alpha-receptor signaling is required for lung growth and the formation of alveoli but not for early lung branching morphogenesis. Dev Dyn. 2002;223(1):155–62. doi:10.​1002/​dvdy.​1225.PubMedCrossRef
39.
Karlsson L, Bondjers C, Betsholtz C. Roles for PDGF-A and sonic hedgehog in development of mesenchymal components of the hair follicle. Development. 1999;126(12):2611–21.PubMed
40.
Karlsson L, Lindahl P, Heath JK, Betsholtz C. Abnormal gastrointestinal development in PDGF-A and PDGFR-(alpha) deficient mice implicates a novel mesenchymal structure with putative instructive properties in villus morphogenesis. Development. 2000;127(16):3457–66.PubMed
41.
Fruttiger M, Karlsson L, Hall AC, Abramsson A, Calver AR, Bostrom H, et al. Defective oligodendrocyte development and severe hypomyelination in PDGF-A knockout mice. Development. 1999;126(3):457–67.PubMed
42.
Gnessi L, Basciani S, Mariani S, Arizzi M, Spera G, Wang C, et al. Leydig cell loss and spermatogenic arrest in platelet-derived growth factor (PDGF)-A–deficient Mice. J Cell Biol. 2000;149(5):1019–26.PubMedPubMedCentralCrossRef
43.
Xu X, Bringas P, Soriano P, Chai Y. PDGFR‐α signaling is critical for tooth cusp and palate morphogenesis. Dev Dyn. 2005;232(1):75–84.PubMedCrossRef
44.
Lindahl P, Hellstrom M, Kalén M, Karlsson L, Pekny M, Pekna M, et al. Paracrine PDGF-B/PDGF-Rbeta signaling controls mesangial cell development in kidney glomeruli. Development. 1998;125(17):3313–22.PubMed
45.
Hellstrom M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development. 1999;126(14):3047–55.PubMed
46.
Bjarnegård M, Enge M, Norlin J, Gustafsdottir S, Fredriksson S, Abramsson A, et al. Endothelium-specific ablation of PDGFB leads to pericyte loss and glomerular, cardiac and placental abnormalities. Development. 2004;131(8):1847–57.PubMedCrossRef
47.
He L, Hristova K. Physical–chemical principles underlying RTK activation, and their implications for human disease. Biochim Biophys Acta (BBA)-Biomembranes. 2012;1818(4):995–1005.CrossRef
48.
Pilz IH, Di Pasquale G, Rzadzinska A, Leppla SH, Chiorini JA. Mutation in the platelet-derived growth factor receptor alpha inhibits adeno-associated virus type 5 transduction. Virology. 2012;428(1):58–63.PubMedPubMedCentralCrossRef
49.
Pauwels D, Klaassen H, Lahortiga I, Kilonda A, Jacobs K, Sweron B, et al. Identification of novel FLT3 kinase inhibitors. Eur J Med Chem. 2013;63:713–21.PubMedCrossRef
50.
Guo J, Cahill MR, McKenna SL, O’Driscoll CM. Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia. Biotechnol Adv. 2014;32(8):1396–409.PubMedCrossRef
51.
Tsao AS, Wei W, Kuhn E, Spencer L, Solis LM, Suraokar M, et al. Immunohistochemical overexpression of platelet-derived growth factor receptor–beta (PDGFR-β) is associated with PDGFRB gene copy number gain in Sarcomatoid non–small-cell lung cancer. Clin Lung Cancer. 2011;12(6):369–74.PubMedPubMedCentralCrossRef
52.
Hofer MD, Fecko A, Shen R, Setlur SR, Pienta KG, Tomlins SA, et al. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia. 2004;6(5):503–12.PubMedPubMedCentralCrossRef
53.
Tsao AS, Harun N, Fujimoto J, Devito V, Lee JJ, Kuhn E, et al. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Ann Diagn Pathol. 2014;18(3):140–5.PubMedPubMedCentralCrossRef
54.
Shimizu A, O’Brien KP, Sjöblom T, Pietras K, Buchdunger E, Collins VP, et al. The dermatofibrosarcoma protuberans-associated collagen type Iα1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 1999;59(15):3719–23.PubMed
55.
Paulsson J, Sjöblom T, Micke P, Pontén F, Landberg G, Heldin C-H, et al. Prognostic significance of stromal platelet-derived growth factor β-receptor expression in human breast cancer. Am J Pathol. 2009;175(1):334–41.PubMedPubMedCentralCrossRef
56.
Seymour L, Bezwoda W. Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer. Breast Cancer Res Treat. 1994;32(2):229–33.PubMedCrossRef
57.
Ariad S, Seymour L, Bezwoda W. Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: correlation with stage and rate of progression. Breast Cancer Res Treat. 1991;20(1):11–7.PubMedCrossRef
58.
Seymour L, Dajee D, Bezwoda W. Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat. 1993;26(3):247–52.PubMedCrossRef
59.
Henriksen R, Funa K, Wilander E, Bäckström T, Ridderheim M, Öberg K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res. 1993;53(19):4550–4.PubMed
60.
Madsen CV, Steffensen KD, Olsen DA, Waldstrom M, Smerdel M, Adimi P, et al. Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab. J Ovarian Res. 2012;5(1):23.PubMedPubMedCentralCrossRef
61.
Kilvaer TK, Smeland E, Valkov A, Sorbye SW, Bremnes RM, Busund L-T, et al. The VEGF-and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk. BMC Clin Pathol. 2014;14(1):5.PubMedPubMedCentralCrossRef
62.
Katano M, Nakamura M, Fujimoto K, Miyazaki K, Morisaki T. Prognostic value of platelet-derived growth factor-A (PDGF-A) in gastric carcinoma. Ann Surg. 1998;227(3):365.PubMedPubMedCentralCrossRef
63.
Ogawa N, Inokuchi M, Takagi Y, Sugita H, Kato K, Kojima K, et al. Clinical significance of platelet derived growth factor-C and-D in gastric cancer. Oncol Lett. 2015;10(6):3495–501.PubMedPubMedCentral
64.
Yang SX, Steinberg SM, Nguyen D, Wu TD, Modrusan Z, Swain SM. Gene expression profile and angiogenic markers correlate with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res. 2008;14(18):5893–9.PubMedPubMedCentralCrossRef
65.
66.
Shen J, Vil MD, Zhang H, Tonra JR, Rong LL, Damoci C, et al. An antibody directed against PDGF receptor β enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody. Biochem Biophys Res Commun. 2007;357(4):1142–7.PubMedCrossRef
67.
Pendergrast PS, Marsh HN, Grate D, Healy JM, Stanton M. Nucleic acid aptamers for target validation and therapeutic applications. J Biomol Tech: JBT. 2005;16(3):224.PubMedPubMedCentral
68.
Galluzzi L, Vacchelli E, Fridman W, Galon J, Sautès-Fridman C, Tartour E, et al. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology. 2012;1:28–37.PubMedPubMedCentralCrossRef
69.
Esposito CL, Camorani S, Iaboni M, Condorelli G, de Franciscis V, Cerchia L. RNA aptamers as highly specific inhibitors of three human RTKs including Axl. EGFR PDGFR Cancer Res. 2012;72(8 Supplement):1100.CrossRef
70.
Qin Y. Targeting the promoter regions of PDGF ligand and receptor. ProQuest; 2008.
71.
Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9(1):28–39.PubMedCrossRef
72.
Schwickart M, Mehrzai F, Pearson J, Shaghasi N, Chavez C, Schneider A, et al. Identification and elimination of target-related matrix interference in a neutralizing anti-drug antibody assay. J Immunol Methods. 2014;403(1):52–61.PubMedCrossRef
73.
Shen J, Vil MD, Prewett M, Damoci C, Zhang H, Li H, et al. Development of a fully human anti-PDGFRβ antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Neoplasia. 2009;11(6):594–604.PubMedPubMedCentralCrossRef
74.
Chang YM, Donovan MJ, Tan W. Using aptamers for cancer biomarker discovery. J Nucleic Acids. 2013;2013.
75.
Bouchard P, Hutabarat R, Thompson K. Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol. 2010;50:237–57.PubMedCrossRef
76.
Cerchia L, Esposito CL, Camorani S, Rienzo A, Stasio L, Insabato L, et al. Targeting Axl with an high-affinity inhibitory aptamer. Mol Ther. 2012;20(12):2291–303.PubMedPubMedCentralCrossRef
77.
Tombelli S, Minunni M, Mascini M. Aptamers-based assays for diagnostics, environmental and food analysis. Biomol Eng. 2007;24(2):191–200.PubMedCrossRef
78.
Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, et al. RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci. 2009;106(21):8695–700.PubMedPubMedCentralCrossRef
79.
Ambesajir A, Kaushik A, Kaushik JJ, Petros ST. RNA interference: a futuristic tool and its therapeutic applications. Saudi J Biol Sci. 2012;19(4):395–403.PubMedPubMedCentralCrossRef
80.
Young SWS, Stenzel M, Jia-Lin Y. Nanoparticle-siRNA: a potential cancer therapy? Critical Reviews in Oncology/Hematology. 2015.
81.
Karnati HK, Yalagala RS, Undi R, Pasupuleti SR, Gutti RK. Therapeutic potential of siRNA and DNAzymes in cancer. Tumor Biol. 2014;35(10):9505–21.CrossRef
82.
Kaulfuβ S, Seemann H, Kampe R, Meyer J, Dressel R, König B, et al. Blockade of the PDGFR family together with SRC leads to diminished proliferation of colorectal cancer cells. Oncotarget. 2013;4(7):1037.PubMedCentralCrossRef
83.
Park YH, Seo SY, Ha M, Ku JH, Kim HH, Kwak C. Inhibition of prostate cancer using RNA interference-directed knockdown of platelet-derived growth factor receptor. Urology. 2011;77(6):1509. e9-e15.PubMedCrossRef
84.
Liu T, Zhang J, Zhang J, Mu X, Su H, Hu X, et al. RNA interference against platelet-derived growth factor receptor α mRNA inhibits fibroblast transdifferentiation in skin lesions of patients with systemic sclerosis. PLoS One. 2013;8(4), e60414.PubMedPubMedCentralCrossRef
85.
Chen J, Wall NR, Kocher K, Duclos N, Fabbro D, Neuberg D, et al. Stable expression of small interfering RNA sensitizes TEL-PDGFβR to inhibition with imatinib or rapamycin. J Clin Investig. 2004;113(12):1784.PubMedPubMedCentralCrossRef
86.
Chen SW, Zhang XR, Wang CZ, Chen WZ, Xie WF, Chen YX. RNA interference targeting the platelet‐derived growth factor receptor β subunit ameliorates experimental hepatic fibrosis in rats. Liver Int. 2008;28(10):1446–57.PubMedPubMedCentralCrossRef
87.
Khvorova A, Reynolds A, Leake D, Marshall W, Read S, Scaringe S. siRNA targeting platelet-derived growth factor receptor beta polypeptide (PDGFR). Google Patents; 2007.
88.
Wu S, Yan G, Zhu W. Evolvement of microRNAs as therapeutic targets for malignant gliomas. INTECH Open Access Publisher; 2013.
89.
Rehman SK, Baldassarre G, Calin GA, Nicoloso MS. MicroRNAs: the jack of all trades. Clin Leuk. 2009;3(1):20–32.CrossRef
90.
Zhang J, Cao R, Zhang Y, Jia T, Cao Y, Wahlberg E. Differential roles of PDGFR-α and PDGFR-β in angiogenesis and vessel stability. FASEB J. 2009;23(1):153–63.PubMedCrossRef
91.
Zhang J, Chintalgattu V, Shih T, Ai D, Xia Y, Khakoo AY. MicroRNA-9 is an activation-induced regulator of PDGFR-beta expression in cardiomyocytes. J Mol Cell Cardiol. 2011;51(3):337–46.PubMedCrossRef
92.
Eberhart JK, He X, Swartz ME, Yan Y-L, Song H, Boling TC, et al. MicroRNA Mirn140 modulates Pdgf signaling during palatogenesis. Nat Genet. 2008;40(3):290–8.PubMedPubMedCentralCrossRef
93.
Peng Y, Guo J-J, Liu Y-M, Wu X-L. MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression. Biosci Rep. 2014;34(3):247–56.CrossRef
94.
Chen D, Li Y, Mei Y, Geng W, Yang J, Hong Q, et al. miR-34a regulates mesangial cell proliferation via the PDGFR-β/Ras-MAPK signaling pathway. Cell Mol Life Sci. 2014;71(20):4027–42.PubMedPubMedCentralCrossRef
95.
Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A, et al. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med. 2003;9(10):1306–12.PubMedCrossRef
96.
Anderson AC, Pollastri MP, Schiffer CA, Peet NP. The challenge of developing robust drugs to overcome resistance. Drug Discov Today. 2011;16(17):755–61.PubMedPubMedCentral
97.
Broxterman HJ, Georgopapadakou NH. Anticancer therapeutics: “addictive” targets, multi-targeted drugs, new drug combinations. Drug Resist Updat. 2005;8(4):183–97.PubMedCrossRef
98.
Fausel C. Targeted chronic myeloid leukemia therapy: seeking a cure. Am J Health Syst Pharm. 2007;64(24 Supplement 15):S9–15.PubMedCrossRef
99.
Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a children’s oncology group study. Pediatr Blood Cancer. 2008;50(2):254–8.PubMedCrossRef
100.
Modi S, Seidman AD, Dickler M, Moasser M, D’Andrea G, Moynahan ME, et al. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat. 2005;90(2):157–63.PubMedCrossRef
101.
Dresemann G, Weller M, Rosenthal MA, Wedding U, Wagner W, Engel E, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neuro-Oncol. 2010;96(3):393–402.CrossRef
102.
Kang Y-K, Ryu M-H, Yoo C, Ryoo B-Y, Kim HJ, Lee JJ, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1175–82.PubMedPubMedCentralCrossRef
103.
Baranowska-Kortylewicz J, Abe M, Pietras K, Kortylewicz ZP, Kurizaki T, Nearman J, et al. Effect of platelet-derived growth factor receptor-β inhibition with STI571 on radioimmunotherapy. Cancer Res. 2005;65(17):7824–31.PubMedPubMedCentral
104.
Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841–51.PubMedCrossRef
105.
Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan I, Vredenburgh JJ, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005;23(36):9359–68.PubMedCrossRef
106.
107.
Sadovnik I, Lierman E, Peter B, Herrmann H, Suppan V, Stefanzl G, et al. Identification of ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA. Exp Hematol. 2014;42(4):282–93. e4.PubMedPubMedCentralCrossRef
108.
Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6(9):714–27.PubMedCrossRef
109.
Glabbeke MV, Verweij J, Casali PG, Simes J, Cesne AL, Reichardt P, et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European organisation for research and treatment of cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC–ISG–AGITG). Eur J Cancer. 2006;42(14):2277–85.PubMedCrossRef
110.
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.PubMedCrossRef
111.
Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26(29):4714–9.PubMedPubMedCentralCrossRef
112.
Procopio G, Verzoni E, Testa I, Nicolai N, Salvioni R, DeBraud F. Experience with sorafenib in the treatment of advanced renal cell carcinoma. Ther Adv Urol. 2012;4(6):303–13.PubMedPubMedCentralCrossRef
113.
Escudier B. Sorafenib for the management of advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2011;11:825–36.PubMedCrossRef
114.
Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(16):2505–12.PubMedCrossRef
115.
Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Bauer M, Jonat W, et al. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR β signalling. Cancer Lett. 2009;273(1):70–9.PubMedCrossRef
116.
Jäger D, Zemanova M, Leonhartsberger N, editors. PREDICT (Patient Characteristics in Renal Cell Carcinoma and Daily Practice Treatment with Sorafenib) global non-interventional study: final report. 34th ESMO and 15th ECCO Meeting; 2012.
117.
Norton K-A, Han Z, Popel AS, Pandey NB. Antiangiogenic cancer drug sunitinib exhibits unexpected proangiogenic effects on endothelial cells. Oncol Targets Ther. 2014;7:1571–82.CrossRef
118.
Tugues S, Koch S, Gualandi L, Li X, Claesson-Welsh L. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Asp Med. 2011;32(2):88–111.CrossRef
119.
van der Graaf WT, Blay J-Y, Chawla SP, Kim D-W, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86.PubMedCrossRef
120.
Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010;11(10):962–72.PubMedPubMedCentralCrossRef
121.
Taylor SK, Chia S, Dent S, Clemons M, Agulnik M, Grenci P, et al. A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the princess Margaret hospital phase II consortium. Oncologist. 2010;15(8):810–8.PubMedPubMedCentralCrossRef
122.
Socinski MA. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer. Cancer Treat Rev. 2011;37(8):611–7.PubMedCrossRef
123.
Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010;119(1):32–7.PubMedCrossRef
124.
Matrana M, Duran C, Shetty A, Xiao L, Atkinson B, Corn P, et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer. 2013;49(15):3169–75.PubMedCrossRef
125.
Hainsworth JD, Rubin MS, Arrowsmith ER, Khatcheressian J, Crane EJ, Franco LA. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial. Clin Genitourin Cancer. 2013;11(3):270–5.PubMedCrossRef
126.
Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014;32:1412–8.PubMedCrossRef
127.
Schutz FA, Choueiri TK, Sternberg CN. Pazopanib: clinical development of a potent anti-angiogenic drug. Crit Rev Oncol/Hematol. 2011;77(3):163–71.CrossRef
128.
H-y C, Guo H, X-w S, Q-y Y, W-y L. Additive effect by combination of Akt inhibitor, MK-2206, and PDGFR inhibitor, tyrphostin AG 1296, in suppressing anaplastic thyroid carcinoma cell viability and motility. Oncol Targets Ther. 2014;7:425–32.
129.
Plé PA, Jung F, Ashton S, Hennequin L, Laine R, Morgentin R, et al. Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases. Bioorg Med Chem Lett. 2012;22(1):262–6.PubMedCrossRef
130.
Lamba G, Ambrale S, Lee B, Gupta R, Rafiyath SM, Liu D. Recent advances and novel agents for gastrointestinal stromal tumor (GIST). J Hematol Oncol. 2012;5(1):21.PubMedPubMedCentralCrossRef
131.
Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood. 2014;123(1):94–100.PubMedPubMedCentralCrossRef
132.
133.
Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, et al. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci. 2014;111(14):5319–24.PubMedPubMedCentralCrossRef
134.
135.
Dai J, Kong Y, Si L, Chi Z, Cui C, Sheng X, et al. Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib. Clin Cancer Res. 2013;19(24):6935–42.PubMedCrossRef
136.
Wang P, Song L, Ge H, Jin P, Jiang Y, Hu W, et al. Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo. Oncol Targets Ther. 2014;7:1761–8.CrossRef
137.
138.
139.
140.
Russell MR, Liu Q, Fatatis A. Targeting the α receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis. Clin Cancer Res. 2010;16(20):5002–10.PubMedCrossRef
141.
142.
Lechleider R, Becerra C, Liang M, Narwal R, Shi L, Conkling P, et al. 404 phase I study of MEDI-575, a fully human monoclonal antibody targeting PDGFR-alpha in subjects with advanced solid tumors. Eur J Cancer Suppl. 2010;8(7):128.CrossRef
143.
144.
145.
Sundaram P, Kurniawan H, Byrne ME, Wower J. Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci. 2013;48(1):259–71.PubMedCrossRef
146.
A phase 2, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous injections of E10030 (Anti-PDGF Pegylated Aptamer) given in combination with Lucentis in subjects with neovascular age-related macular degeneration. http://​clinicaltrials.​gov/​show/​NCT01089517 November 24, 2014.
147.
148.
149.
Davids M, Charlton A, Ng S-S, Chong M-L, Laubscher K, Dar M, et al. Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma. J Clin Oncol. 2009;27(26):e97–100.PubMedCrossRef
Metadata
Title
Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers
Authors
Kwaku Appiah-Kubi
Ying Wang
Hai Qian
Min Wu
Xiaoyuan Yao
Yan Wu
Yongchang Chen
Publication date
01-08-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 8/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5069-z

Other articles of this Issue 8/2016

Tumor Biology 8/2016 Go to the issue

Original Article

Armc8 regulates the invasive ability of hepatocellular carcinoma through E-cadherin/catenin complex

Original Article

The value of serum RASSF10 hypermethylation as a diagnostic and prognostic tool for gastric cancer

Original Article

Association between p21 Ser31Arg polymorphism and the development of cervical lesion in women infected with high risk HPV

Original Article

Pyruvate dehydrogenase B promoted the growth and migration of the nasopharyngeal carcinoma cells

Original Article

Crystal structure and chemotherapeutic efficacy of the novel compound, gallium tetrachloride betaine, against breast cancer using nanotechnology

Review

What gastric cancer proteomic studies show about gastric carcinogenesis?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits